Walter E Finkbeiner
Overview
Explore the profile of Walter E Finkbeiner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
1704
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Koh K, Siddiqui S, Cheng D, Bonser L, Sun D, Zlock L, et al.
Am J Respir Cell Mol Biol
. 2019 Oct;
62(3):373-381.
PMID: 31596609
Primary human bronchial epithelial cell (HBEC) cultures are a useful model for studies of lung health and major airway diseases. However, mechanistic studies have been limited by our ability to...
12.
Sun D, Tasca A, Haas M, Baltazar G, Harland R, Finkbeiner W, et al.
Cells Tissues Organs
. 2018 Oct;
205(5-6):279-292.
PMID: 30300884
Na+/H+ exchangers (NHEs) represent a highly conserved family of ion transporters that regulate pH homeostasis. NHEs as well as other proton transporters were previously linked to the regulation of the...
13.
Phuan P, Son J, Tan J, Li C, Musante I, Zlock L, et al.
J Cyst Fibros
. 2018 Jun;
17(5):595-606.
PMID: 29903467
Background: Current modulator therapies for some cystic fibrosis-causing CFTR mutants, including N1303K, have limited efficacy. We provide evidence here to support combination potentiator (co-potentiator) therapy for mutant CFTRs that are...
14.
Phuan P, Veit G, Tan J, Roldan A, Finkbeiner W, Haggie P, et al.
SLAS Discov
. 2018 Mar;
23(8):823-831.
PMID: 29533733
The most common cystic fibrosis-causing mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) is deletion of phenylalanine at residue 508 (∆F508). The ∆F508 mutation impairs folding of nucleotide binding...
15.
McGarry M, Illek B, Ly N, Zlock L, Olshansky S, Moreno C, et al.
Pediatr Pulmonol
. 2017 Jan;
52(4):472-479.
PMID: 28068001
Rationale: Ivacaftor, a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator, decreases sweat chloride concentration, and improves pulmonary function in 6% of cystic fibrosis (CF) patients with specific CFTR mutations. Ivacaftor...
16.
Haggie P, Phuan P, Tan J, Xu H, Avramescu R, Perdomo D, et al.
J Biol Chem
. 2016 Nov;
292(3):771-785.
PMID: 27895116
W1282X is the fifth most common cystic fibrosis transmembrane regulator (CFTR) mutation that causes cystic fibrosis. Here, we investigated the utility of a small molecule corrector/potentiator strategy, as used for...
17.
Zhang L, Gallup M, Zlock L, Feeling Chen Y, Finkbeiner W, McNamara N
Am J Pathol
. 2016 Oct;
186(12):3146-3159.
PMID: 27765636
Lung cancer is the leading cause of cancer-related death, and 87% of these deaths are directly attributable to smoking. Using three-dimensional cultures of primary human bronchial epithelial cells, we demonstrated...
18.
Boecking C, Drey E, Kerns J, Finkbeiner W
Arch Pathol Lab Med
. 2016 Oct;
141(2):267-273.
PMID: 27763778
Context: -Despite increased use of dilation and evacuation in the setting of fetuses with developmental anomalies, the pathology examination of fragmented specimens obtained by this technique has been understudied. Objectives:...
19.
Haggie P, Phuan P, Tan J, Zlock L, Finkbeiner W, Verkman A
FASEB J
. 2016 Mar;
30(6):2187-97.
PMID: 26932931
Pendrin (SLC26A4) is a Cl(-)/anion exchanger expressed in the epithelium of inflamed airways where it is thought to facilitate Cl(-) absorption and HCO3 (-) secretion. Studies using pendrin knockout mice...
20.
Phuan P, Veit G, Tan J, Finkbeiner W, Lukacs G, Verkman A
Mol Pharmacol
. 2015 Aug;
88(4):791-9.
PMID: 26245207
Combination drug therapies under development for cystic fibrosis caused by the ∆F508 mutation in cystic fibrosis transmembrane conductance regulator (CFTR) include a "corrector" to improve its cellular processing and a...